These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7753914)

  • 1. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: in vivo pharmacological studies.
    Castro-Faria-Neto HC; Araújo CV; Moreira S; Bozza PT; Thomas G; Barbosa-Filho JM; Cordeiro RS; Tibiriçá EV
    Planta Med; 1995 Apr; 61(2):106-12. PubMed ID: 7753914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: binding and in vitro functional studies.
    Castro-Faria-Neto HC; Bozza PT; Cruz HN; Silva CL; Violante FA; Barbosa-Filho JM; Thomas G; Martins MA; Tibiriçá EV; Noel F
    Planta Med; 1995 Apr; 61(2):101-5. PubMed ID: 7753913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yangambin, a lignan obtained from Ocotea duckei, differentiates putative PAF receptor subtypes in the gastrointestinal tract of rats.
    Jesus-Morais CM; Assis EF; Cordeiro RS; Barbosa-Filho JM; Lima WT; Silva ZL; Bozza PT; Castro-Faria-Neto HC
    Planta Med; 2000 Apr; 66(3):211-6. PubMed ID: 10821044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological evidence for the putative existence of two different subtypes of PAF receptors on platelets and leukocytes; studies with yangambin.
    Herbert JM; Castro-Faria-Neto HC; Barbosa-Filho JM; Cordeiro RS; Tibiriça E
    J Lipid Mediat Cell Signal; 1997 Sep; 17(1):1-14. PubMed ID: 9302650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of yangambin on cardiovascular hyporeactivity to catecholamines in rats with endotoxin-induced shock.
    Araújo CV; Barbosa-Filho JM; Cordeiro RS; Tibiriçá E
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Mar; 363(3):267-75. PubMed ID: 11284440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of Yangambin - a naturally occurring platelet-activating factor (PAF) receptor antagonist - on anaphylactic shock in rats.
    Ribeiro R; Carvalho FA; Barbosa-Filho JM; Cordeiro RS; Tibiriçá EV
    Phytomedicine; 1996 Nov; 3(3):249-56. PubMed ID: 23195079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-allergic properties of the natural PAF antagonist yangambin.
    Serra MF; Diaz BL; Barreto EO; Pereira AP; Lima MC; Barbosa-Filho JM; Cordeiro RS; Martins MA; de Silva PM
    Planta Med; 1997 Jun; 63(3):207-12. PubMed ID: 9225600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonistic effect of yangambin on platelet-activating factor (PAF)-induced cardiovascular collapse.
    Tibiriçá EV; Mosquera K; Abreu M; Ribeiro R; Carvalho FA; Barbosa-Filho JM; Cordeiro RS
    Phytomedicine; 1996 Jan; 2(3):235-42. PubMed ID: 23194622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
    Floch A; Tahraoui L; Sedivy P; Cavero I
    J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular properties of yangambin, a lignan isolated from Brazilian plants.
    Tibiriçá E
    Cardiovasc Drug Rev; 2001; 19(4):313-28. PubMed ID: 11830750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
    Brecht HM; Adamus WS; Heuer HO; Birke FW; Kempe ER
    Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
    J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
    J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiinflammatory and antiallodynic actions of the lignan niranthin isolated from Phyllanthus amarus. Evidence for interaction with platelet activating factor receptor.
    Kassuya CA; Silvestre A; Menezes-de-Lima O; Marotta DM; Rehder VL; Calixto JB
    Eur J Pharmacol; 2006 Sep; 546(1-3):182-8. PubMed ID: 16925995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC; Seldon PM; Barnes PJ; Giembycz MA
    Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes.
    Herbert JM; Laplace MC; Cailleau C; Maffrand JP
    J Lipid Mediat; 1993 May; 7(1):57-78. PubMed ID: 8395255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
    Herbert JM; Laplace MC; Maffrand JP
    J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.